c-MYC Expression and Treatment Response in Medulloblastoma
Author Information
Author(s): von Bueren André O, Oehler Christoph, Shalaby Tarek, von Hoff Katja, Pruschy Martin, Seifert Burkhardt, Gerber Nicolas U, Warmuth-Metz Monika, Stearns Duncan, Eberhart Charles G, Kortmann Rolf D, Rutkowski Stefan, Grotzer Michael A
Primary Institution: University Children's Hospital, Zurich, Switzerland
Hypothesis
To study whether and how c-MYC expression determines response to radio- and chemotherapy in childhood medulloblastoma.
Conclusion
c-MYC sensitizes MB cells to some anti-cancer treatments in vitro, but this effect was not observed in postoperative residual tumors.
Supporting Evidence
- DAOY and UW228 cells expressing high levels of c-MYC showed significantly higher cytotoxicity to cisplatin and etoposide.
- Apoptotic cell death was enhanced in DAOY cells expressing high levels of c-MYC.
- c-MYC mRNA expression was similar in primary MB samples of responders and non-responders.
Takeaway
This study looked at how a protein called c-MYC affects the way brain cancer cells respond to treatments like radiation and chemotherapy. They found that while c-MYC helps the cancer cells die in lab tests, it didn't seem to help in real patients after surgery.
Methodology
The study used human MB cell lines engineered to express different levels of c-MYC and assessed their sensitivity to various treatments through several assays.
Limitations
The study had a small number of patients for assessing the relationship between c-MYC expression and treatment response.
Participant Demographics
Patients aged 3 to 21 years with histologically proven medulloblastoma.
Statistical Information
P-Value
0.50
Confidence Interval
95% CI 0.008-30.0 and 95% CI 0.14-23.5
Statistical Significance
p = 0.50
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website